NRAS

GTPase NRas · P01111 · NRAS on Sugi Atlas →

15,275 patent compounds predicted against NRAS, 11,842 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL376585 SCHEMBL376585 0.58 10/20
SCHEMBL2054090 SCHEMBL2054090 0.51 10/20
SCHEMBL2054091 SCHEMBL2054091 0.51 10/20
SCHEMBL10238348 SCHEMBL10238348 0.51 10/20
SCHEMBL2037292 SCHEMBL2037292 0.49 10/20
SCHEMBL10238541 SCHEMBL10238541 0.49 10/20
SCHEMBL10239525 SCHEMBL10239525 0.49 10/20
SCHEMBL10239822 SCHEMBL10239822 0.46 10/20
SCHEMBL376715 SCHEMBL376715 0.53 9/20
SCHEMBL10239476 SCHEMBL10239476 0.52 9/20
SCHEMBL10239502 SCHEMBL10239502 0.51 9/20
SCHEMBL15193127 SCHEMBL15193127 0.50 9/20
SCHEMBL15193129 SCHEMBL15193129 0.50 9/20
SCHEMBL10238387 SCHEMBL10238387 0.46 9/20
SCHEMBL10239487 SCHEMBL10239487 0.45 9/20
SCHEMBL376666 SCHEMBL376666 0.58 8/20
SCHEMBL376740 SCHEMBL376740 0.54 8/20
SCHEMBL10238526 SCHEMBL10238526 0.51 8/20
SCHEMBL10239097 SCHEMBL10239097 0.51 8/20
SCHEMBL376342 SCHEMBL376342 0.49 8/20

Clinical trials — most relevant to NRAS by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer PHASE4UNKNOWN
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer PHASE2/PHASE3COMPLETED
SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer PHASE2COMPLETED
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery PHASE2COMPLETED
High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies PHASE2COMPLETED
Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma PHASE2COMPLETED
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. PHASE2RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Study of HL-085 in NRAS Mutant Advanced Melanoma PHASE1/PHASE2COMPLETED
Study of MEK162 for Children With Low-Grade Gliomas PHASE1/PHASE2COMPLETED
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS PHASE1/PHASE2RECRUITING
PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities PHASE2UNKNOWN
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial PHASE2ACTIVE_NOT_RECRUITING
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma PHASE2COMPLETED
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS PHASE2RECRUITING
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors PHASE2RECRUITING
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial PHASE2RECRUITING
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma PHASE2COMPLETED
HL-085 in NRAS-mutated Advanced Melanoma PHASE2COMPLETED
A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies PHASE1RECRUITING
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors PHASE1RECRUITING
Phase I Trial of VS-6766 Alone and in Combination With Everolimus PHASE1COMPLETED
Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers PHASE1COMPLETED
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients PHASE1UNKNOWN
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors PHASE1UNKNOWN
KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009 nanCOMPLETED
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma nanAVAILABLE
Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a NRAS binder may also engage these)

ProteinNameSimilarity
Q2MJK3 1.000 Q2MJK3 →
Q95ME4 1.000 Q95ME4 →
P12825 1.000 P12825 →
Q04970 1.000 Q04970 →
P08556 1.000 P08556 →
Q5RD87 1.000 Q5RD87 →
P79737 1.000 P79737 →
Q61411 1.000 Q61411 →
Q5F352 1.000 Q5F352 →
P32883 1.000 P32883 →
P23175 1.000 P23175 →
P83831 1.000 P83831 →
P20171 1.000 P20171 →
KRAS GTPase KRas 1.000 landscape →
B4GFJ8 1.000 B4GFJ8 →
P01113 1.000 P01113 →
P08646 1.000 P08646 →
P08642 1.000 P08642 →
B3M185 1.000 B3M185 →
B3NZR4 1.000 B3NZR4 →
P83832 1.000 P83832 →
B4PUP5 1.000 B4PUP5 →
HRAS GTPase HRas 1.000 landscape →
Q05147 1.000 Q05147 →
P18262 1.000 P18262 →
Q91806 1.000 Q91806 →
B4JFU8 1.000 B4JFU8 →
P08644 1.000 P08644 →
Q5EFX7 0.998 Q5EFX7 →
P22981 0.998 P22981 →